Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Equity Average (2016 - 2025)

Sangamo Therapeutics has reported Equity Average over the past 15 years, most recently at -$4.0 million for Q4 2025.

  • Quarterly results put Equity Average at -$4.0 million for Q4 2025, down 112.96% from a year ago — trailing twelve months through Dec 2025 was -$4.0 million (down 112.96% YoY), and the annual figure for FY2025 was $4.3 million, down 91.95%.
  • Equity Average for Q4 2025 was -$4.0 million at Sangamo Therapeutics, down from $12.9 million in the prior quarter.
  • Over the last five years, Equity Average for SGMO hit a ceiling of $483.4 million in Q1 2021 and a floor of -$4.0 million in Q4 2025.
  • Median Equity Average over the past 5 years was $234.5 million (2023), compared with a mean of $207.7 million.
  • Biggest five-year swings in Equity Average: grew 16.88% in 2021 and later crashed 112.96% in 2025.
  • Sangamo Therapeutics' Equity Average stood at $390.7 million in 2021, then decreased by 22.68% to $302.1 million in 2022, then crashed by 63.95% to $108.9 million in 2023, then plummeted by 71.58% to $31.0 million in 2024, then plummeted by 112.96% to -$4.0 million in 2025.
  • The last three reported values for Equity Average were -$4.0 million (Q4 2025), $12.9 million (Q3 2025), and $12.3 million (Q2 2025) per Business Quant data.